This double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of 12 months of adjuvant durvalumab, an immune-checkpoint inhibitor (ICI) targeting PD-L1, after definitive CRT with a platinum-based regimen, for unresectable NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.